Notably, several of these agents have established connections to glycolytic metabolism: Olaparib, a PARP inhibitor, has been shown to synergize with glycolysis inhibitors by exploiting metabolic vulnerabilities in cancer cells; doramapimod (p38 MAPK inhibitor) can modulate glycolytic enzyme expression and glucose metabolism through p38-mediated pathways; and ruxolitinib (JAK inhibitor) affects metabolic reprogramming by influencing STAT-mediated transcription of glycolytic genes (Figure 8B). Here, HK1 is linked to cancer.